GlobalGov › Germany › Pharmaceuticals › Solicitation

Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2024-08 - Darbepoetin alfa

Health, Health, Health · Germany government procurement

Closed July 31, 2026. GlobalGov surfaces government procurement from around the world, including the markets your competitors overlook.

Closed
Status

About this record

The issuing agency did not publish a description for this notice. The full record as GlobalGov received it is below.

Your competitors are watching the same crowded contracts everyone else is. Track live opportunities like this one worldwide, set deadline alerts, and win where they aren’t. Free for 14 days, no card.

Start Free

Solicitation Details

Issuing agencyHealth, Health, Health
CountryGermany
CategoryPharmaceuticals
PublishedJune 19, 2024
Procurement stageActive solicitation
ClosedJuly 31, 2026
StatusClosed — no longer accepting responses
Original languageGerman — members read it in their own language
Official sourceView original notice
Last verifiedOctober 11, 2026

Source: Tenders Electronic Daily (TED), © European Union. Notice content reused under Commission Decision 2011/833/EU; editorial content licensed CC BY 4.0. GlobalGov is not affiliated with the European Union.

Germany market overview →Pharmaceuticals tenders in Germany →Browse all categories →

Browse Similar Open Opportunities in Germany

Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130 a Abs. 8 SGB V mit dem Wirkstoff Mycophenolsäure in der Darreichungsform PSE.
Germany – Pharmaceutical products – Abschluss eines nicht exklusiven Rabattvertrages nach § 130a Abs. 8 SGB V zu Arzneimitteln mit der Wirkstoffkombination aus Brinzolamid und Brimonidin (ATC-Code: S01EC24).
Germany – Pharmaceutical products – Arzneimittel mit dem Wirkstoff Infliximab (ATC: L04AB02 - in der Darreichungsform Injektionslösung)
Germany – Pharmaceutical products – Arzneimittel mit der Wirkstoffkombination Metoprolol und Hydrochlorothiazid (ATC: C07BB22)
Germany – Pharmaceutical products – Arzneimittel mit dem Wirkstoff Leuprorelin (ATC: L02AE02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ambrisentan (ATC-Code nach WHO: C02KX02)
Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Rivaroxaban Filmtabletten, ausgenommen in der Wirkstärke 2,5 mg, ATC B01AF01
Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge zum Wirkstoff Clonidin, ATC C02AC01

See every Germany Pharmaceuticals opportunity your competition is missing. Free for 14 days.

Get real-time alerts, competitive intelligence, and deadline tracking for this and every market worldwide.

Start Free Trial — No Card Required

Free 14-day trial · no card required

See who is already competing here →

Get a free Germany Pharmaceuticals intelligence report in your inbox

A personalized report on Germany Pharmaceuticals opportunities, emailed in 5-10 minutes. One per month, no account needed.